Free Trial

Kymera Therapeutics (KYMR) Stock Price, News & Analysis

-0.70 (-1.60%)
(As of 07/19/2024 ET)
Today's Range
50-Day Range
52-Week Range
528,429 shs
Average Volume
686,858 shs
Market Capitalization
$2.64 billion
P/E Ratio
Dividend Yield
Price Target

Kymera Therapeutics MarketRank™ Stock Analysis

Analyst Rating
2.46 Rating Score
2.3% Downside
$42.09 Price Target
Short Interest
15.29% of Shares Sold Short
Dividend Strength
News Sentiment
0.68mentions of Kymera Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$19.28 M Sold Last Quarter
Proj. Earnings Growth
From ($2.86) to ($3.15) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.18 out of 5 stars

Medical Sector

880th out of 896 stocks

Biological Products, Except Diagnostic Industry

148th out of 152 stocks

KYMR stock logo

About Kymera Therapeutics Stock (NASDAQ:KYMR)

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

KYMR Stock Price History

KYMR Stock News Headlines

[URGENT] Altcoin Winning Picks
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
[URGENT] Altcoin Winning Picks
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
See More Headlines
Receive KYMR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kymera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
13 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$78.59 million
Book Value
$7.12 per share


Free Float
Market Cap
$2.69 billion
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Dr. Bruce L. Booth DPHIL (Age 50)
    Ph.D., Co-Founder & Independent Chairman
    Comp: $75k
  • Dr. Nello Mainolfi M.D. (Age 45)
    Ph.D., Co-Founder, President, CEO & Director
    Comp: $1.08M
  • Mr. Bruce N. Jacobs CFAMr. Bruce N. Jacobs CFA
    Chief Financial Officer
  • Dr. Jeremy G. Chadwick Ph.D. (Age 61)
    Chief Operating Officer
    Comp: $883k
  • Ms. Ellen V. Chiniara Esq. (Age 65)
    J.D., Chief Legal Officer & Corporate Secretary
    Comp: $640.35k
  • Dr. Jared A. Gollob M.D. (Age 59)
    Chief Medical Officer
    Comp: $723.6k
  • Ms. Karen Weisbach
    Head of People & Culture
  • Dr. Juliet Williams B.A Ph.D.
    Head of Research

KYMR Stock Analysis - Frequently Asked Questions

How have KYMR shares performed this year?

Kymera Therapeutics' stock was trading at $25.46 at the beginning of the year. Since then, KYMR shares have increased by 69.3% and is now trading at $43.10.
View the best growth stocks for 2024 here

How were Kymera Therapeutics' earnings last quarter?

Kymera Therapeutics, Inc. (NASDAQ:KYMR) issued its earnings results on Thursday, May, 2nd. The company reported ($0.69) EPS for the quarter, beating analysts' consensus estimates of ($0.73) by $0.04. Kymera Therapeutics's revenue for the quarter was up 8.4% compared to the same quarter last year.

When did Kymera Therapeutics IPO?

Kymera Therapeutics (KYMR) raised $126 million in an IPO on Friday, August 21st 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cowen and Guggenheim Securities served as the underwriters for the IPO.

Who are Kymera Therapeutics' major shareholders?

Kymera Therapeutics' top institutional investors include Harbor Capital Advisors Inc. (0.05%), SG Americas Securities LLC (0.02%) and Keudell Morrison Wealth Management (0.01%). Insiders that own company stock include Venture Fund X LP Atlas, Bvf Partners L P/Il, Bruce Booth, Bruce N Jacobs, Jared Gollob, Ellen Chiniara, Richard Chesworth, Joanna Horobin, Jeffrey W Albers and Nello Mainolfi.
View institutional ownership trends

How do I buy shares of Kymera Therapeutics?

Shares of KYMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Kymera Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kymera Therapeutics investors own include Harbor Custom Development (HCDI), Gores Holdings V (GRSVU), FS Development (FSDC), Freeline Therapeutics (FRLN), Duck Creek Technologies (DCT), CureVac (CVAC) and Checkmate Pharmaceuticals (CMPI).

This page (NASDAQ:KYMR) was last updated on 7/19/2024 by Staff

From Our Partners